Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy (NCT01843504) | Clinical Trial Compass
CompletedPhase 2
Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy
United States29 participantsStarted 2014-01
Plain-language summary
The goal of this study is to find an effective treatment for chronic patellar tendinopathy (PT). Investigators will conduct a 32-week randomized controlled clinical trial to determine whether platelet rich plasma (PRP) injections improve disease-specific clinical outcomes with correlation to a new method of ultrasound (US) imaging assessment called Acoustoelastography (AE). Positive findings of PRP compared to control would suggest future larger scale studies to help establish an optimal protocol for the nonsurgical management of PT.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. age18-65
✓. chronic (\>3months) patellar tendon pain;
✓. clinical exam findings consistent with PT;
✓. self-reported failure of supervised physical therapy;
✓. self-reported failure of at least 2 of the most common treatments (NSAIDs, relative rest, ice, bracing) for patellar tendinopathy.
Exclusion criteria
✕. inability to comply with follow-up requirements of study,
✕. history of bleeding disorders, low-platelet counts, other hematologic conditions;
✕. knee pain due to another possible etiology(e.g., degenerative joint disease);
✕. current or recent use of anticoagulation or immunosuppressive therapy;
✕. known allergy to acetaminophen or Lidocaine;
What they're measuring
1
Change in Victorian Institute of Sport Assessment-Patellar (VISAP) Score
Timeframe: 0, 4, 8, 12, 16, and 32 weeks
2
Change in International Knee Documentation Committee (IKDC) Score